CJC-1295 with DAC

🔬Kas yra CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids. The DAC modification enables covalent binding to serum albumin, extending its half-life to approximately 6–8 days compared to minutes for native GHRH. This prolonged activity allows for sustained, elevated growth hormone secretion from the anterior pituitary through continuous stimulation of the GHRH receptor (GHRHR). Research suggests it promotes steady-state GH and IGF-1 elevation, making it a subject of interest in studies on anabolic processes, body composition, and tissue repair.

📊Klinikiniai tyrimai ir rezultatai

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analogue that binds to albumin in the bloodstream, extending its half-life to 6-8 days:

• ▪Clinical studies demonstrated sustained elevation of GH and IGF-1 levels for 6-14 days following a single subcutaneous injection, with peak IGF-1 increases of 200-300% from baseline
• ▪The DAC modification enables albumin binding, extending the biological half-life from ~30 minutes (no DAC) to ~6-8 days, allowing once-weekly dosing protocols
• ▪Produced consistent, sustained IGF-1 elevation without the sharp peaks and troughs seen with shorter-acting GHRH analogues
• ▪Increased mean 24-hour GH concentration by 2-10 fold depending on dose, with effects persisting for up to 2 weeks post-injection
• ▪Demonstrated excellent tolerability with no serious adverse events in Phase I/II clinical trials
• ▪Maintained GH pulsatility despite sustained elevation, preserving some degree of physiological GH secretion pattern

CJC-1295 with DAC provides the longest-acting GHRH stimulation available, ideal for research requiring sustained, stable GH/IGF-1 elevation with minimal dosing frequency.

🏆Privalumai

• Extended Half-Life of 6-8 Days – Enables convenient once-weekly dosing protocols
• Sustained IGF-1 Elevation – 200-300% increase lasting up to 2 weeks per injection
• Stable GH/IGF-1 Levels – Avoids sharp peaks and troughs of short-acting analogues
• Convenient Dosing – Single weekly injection vs multiple daily doses required by non-DAC variants
• Well-Tolerated – No serious adverse events in clinical trials across dose ranges
• Preserved GH Pulsatility – Maintains some physiological GH secretion pattern despite sustained elevation

⚠️Galimas šalutinis poveikis

• ▪Generally well-tolerated in research – most observed effects are mild and transient
• ▪Water retention and mild peripheral edema – consistent with sustained GH elevation and commonly dose-dependent
• ▪Transient flushing, warmth, or tingling sensation shortly after administration
• ▪Mild headache reported in some research protocols, typically resolving within hours
• ▪Due to its prolonged half-life and continuous GH stimulation, research suggests caution regarding glucose metabolism – elevated fasting blood sugar has been observed and glucose monitoring is considered prudent
• ▪In subjects with a family history of malignancies, researchers note that sustained IGF-1 elevation may theoretically promote growth of pre-existing neoplasms – cyclical use patterns are often preferred in such contexts

🎯Idealiai tinka

• →Long-term GH optimization with minimal dosing frequency
• →Sustained IGF-1 elevation research requiring stable levels
• →Convenience-focused anti-aging and recovery protocols
• →Body composition improvement over extended timeframes
• →Researchers preferring weekly vs daily injection protocols
• →Combining with GHRP peptides for enhanced but less frequent GH stimulation